A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
A subcutaneous formulation of the anti-CD20 antibody rituximab has been developed. Fixed-dose subcutaneous rituximab delivers non-inferior serum trough concentrations (Ctrough ), ensuring similar target saturation and comparable efficacy/safety to intravenous rituximab, but with simplified and shortened preparation and administration. We aimed to characterize the pharmacokinetic and exposure-response properties of subcutaneous rituximab. Data from two clinical trials were analyzed to describedoi:10.1002/psp4.12665 pmid:34110098 pmcid:PMC8376135 fatcat:o5ougchlurejtmuixzca2xyxkq